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Urinary Nerve Growth Factor Levels in Overactive
Bladder Syndrome and Lower Urinary Tract Disorders
Hsin-Tzu Liu,1,2 Chia-Yen Chen,1 Hann-Chorng Kuo1*
Overactive bladder (OAB) is a syndrome based on self-reported symptoms of urgency and frequency with or
without urge incontinence. Although urgency is the core symptom of OAB, patients might have difficulty to
distinguish urgency from the urge to void. Urodynamic study is a useful diagnostic tool to discover detrusor
overactivity (DO) in patients with OAB; however, not all OAB patients have DO. Therefore, a more objec-
tive and non-invasive way to diagnose and assess OAB including DO is needed. Recent research has fo-
cused on urinary biomarkers in assessment of OAB. Urinary nerve growth factor (NGF) level increases in
patients with OAB-wet, bladder outlet obstruction, mixed urinary incontinence and urodynamic DO.
Urinary NGF levels are correlated with severity of OAB symptoms. In patients with OAB and DO who have
been well treated with antimuscarinics or botulinum toxin injection, urinary NGF levels have been shown
to decrease significantly in association with reduction of urgency severity. However, not all patients with
OAB have an elevated urinary NGF level. It might also be increased in patients with interstitial
cystitis/painful bladder syndrome, cerebrovascular accident and lower urinary tract diseases such as uri-
nary tract stone, bacterial infection and urothelial tumor. It is possible to use urinary NGF levels as a bio-
marker for diagnosis of OAB as well as for the assessment of therapeutic outcome in patients with OAB or
DO. Here, we review the latest medical advances in this field.
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Overactive bladder (OAB) syndrome is a condition
of urinary urgency and frequency with or without
urge incontinence, and urgency is the core symp-
tom for the presence of OAB.1 Clinical assessment
of OAB severity or grade is based on subjectively
reported symptoms and patients might not be 
able to distinguish urgency from the urge to
void.2,3 Patients with OAB might have detrusor
overactivity (DO) or sensory urgency. However,
only 69% of men and 44% of women with ur-
gency (OAB-dry) have DO, whereas 90% of men
and 58% of women with urgency and urgency
incontinence (OAB-wet) have DO.4 It is possible
that many patients with increased bladder sensa-
tion without urgency are grouped into OAB-dry,
which might cause a high non-response rate in
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clinical therapeutic trials.5,6 It is necessary to de-
velop a better way to diagnose OAB and assess
therapeutic outcome in patients with OAB.
Nerve Growth Factor in the Lower
Urinary Tract
Nerve growth factor (NGF) is a small secreted pro-
tein that induces differentiation and survival of
particular target neurons. NGF can be produced
from the urinary bladder through protein-kinase-
C- and protein-kinase-A-dependent intracellular
pathways that play physiological and pathophys-
iological roles in the lower urinary tract.7 NGF
can sensitize afferent nerves and induce bladder
hyperactivity8,9 and is linked to mechanical
stretch and reflex bladder activity.10 The levels of
neurotrophic factors including NGF increase in rat
bladders, as well as in the lumbosacral spinal cord
and dorsal root ganglia (DRGs), after spinal cord
injury (SCI) and cyclophosphamide-induced cys-
titis.8,11 Chronic administration of NGF into the
spinal cord or bladder of rats induces bladder hy-
peractivity and increases the firing frequency of
bladder afferent neurons.12–14 Intravesical instilla-
tion of NGF in rats reduces mechanical hypersen-
sitivity that can be reversed by NGF antiserum.15
In long-term diabetic rats induced by streptozo-
tocin, the mean NGF levels in bladder tissue and
lumbosacral DRGs were significantly lower than
in the controls, and after treatment of diabetes
the reduced NGF levels returned to normal.16,17
Increased levels of NGF have also been re-
ported in the bladder urothelium and smooth
muscle and urine of patients with interstitial cys-
titis/painful bladder syndrome (IC/PBS), sensory
urgency, and DO18–20 (Figure 1). In patients with
neurogenic DO (NDO), NGF level in bladder tissue
increases and decreases after detrusor botulinum
neurotoxin A (BoNT-A) injection, in association
with decreased detrusor contractility.21 This find-
ing further provides evidence that NGF is involved
in visceral afferent nerve transmission and can be
modulated by treatment for NDO. These observa-
tions in animal models and humans suggest that
NGF has a potential role as a urinary biomarker
for the diagnostic and therapeutic implications
of lower urinary tract dysfunction.
NGF in the Urine
Clinical and experimental data have indicated a di-
rect link between increased levels of NGF in the
bladder tissue and urine, and painful inflamma-
tory conditions in the lower urinary tract, such as
bladder outlet obstruction (BOO), OAB, IC/PBS,
and chronic prostatitis.18,22,23 Bladder inflamma-
tion results in altered NGF levels in the bladder
and morphological changes in sensory and motor
neurons that innervate the bladder.24 Denervation
of rat bladder results in transient increases in blad-
der NGF level, which indicates that innervation
influences tissue levels of NGF in the bladder.25
Previous studies of NGF in OAB or DO usually
have measured bladder tissue level, which are ele-
vated in patients with idiopathic DO (IDO), men
with benign prostatic hyperplasia (BPH) and
women with IC/PBS.26 A recent study that has
measured NGF concentration using enzyme-
linked immunosorbent assay (ELISA) in superfi-
cial bladder biopsies from 12 women with
urodynamic DO and 15 without, did not show a
significant correlation between bladder NGF level
and DO.19 It is difficult to standardize the quan-
tity of NGF in epithelium, suburothelium and
muscle with a bladder biopsy, and a simpler and
safer urine level of NGF measurement is in fact a
better assay and one that can be standardized.
Visceral epithelia have been demonstrated as a
major source of NGF production, and NGF might
regulate the function of adult visceral sensory and
motor neurons.27 Using gene transfer techniques
in rats, a transient increase in NGF expression
without associated inflammation sensitizes vis-
ceral reflex pathways, which leads to bladder over-
activity.12 Exogenous overexpression of NGF in
the urinary bladder produces DO and nociceptive
Fos expression in the lumbosacral spinal cord.28
Stretching of the urothelium during bladder dis-
tention might induce production of NGF in the
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bladder tissue and secretion into the urine. It is
rational to hypothesize that NGF produced in the
urothelium and suburothelium can be secreted
into the bladder lumen.10 Kim and Park found
that urinary NGF levels are increased in men and
women with OAB syndrome.29 Yokoyama evalu-
ated urine NGF in patients with OAB, BOO, and
NDO.30 Although NGF levels in the bladder tis-
sue and urine might not correlate well, an inter-
action between urinary NGF and sensory fibers,
as well as an effect on detrusor hyperactivity is
probable.
Detrusor injection of BoNT-A in patients with
IDO might inhibit NGF production in the
urothelium and suburothelium and therefore
decrease the urinary NGF levels as well as reduce
the urgency sensation.31 Measurement of NGF in
the urine is likely to be a more relevant and sen-
sitive biomarker for OAB than is bladder tissue
NGF levels. If the urinary NGF levels differ among
normal controls and patients with increased blad-
der sensation, OAB-dry and OAB-wet, then uri-
nary NGF levels could be a convenient biomarker
for diagnosis or assessment of the therapeutic
outcome of OAB.
Measurement of Urinary NGF Levels
Measurement of urinary NGF levels is performed
by ELISA using non-diluted urine samples. Voided
urine is put on ice immediately and centrifuged 
at 3,000 g for 10 minutes at 4°C. The supernatant
is separated into aliquots in 1.5-mL tubes and 
preserved in a −80°C freezer. At the same time,
3 mL urine is taken to measure urinary creatinine
level. Urinary NGF concentration is determined
using the Emax ImmunoAssay System (Promega,
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Figure 1. Increased nerve growth factor immunohistochemistry staining in the urothelium and suburothelium of overac-
tive bladder.
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Madison, WI, USA) with a specific and highly sen-
sitive ELISA kit, which has a minimum sensitivity
of 7.8 pg/mL. The amount of NGF in urine sam-
ples that falls below the detection limits of the
NGF assay is extracted from an NGF standard
curve. We run samples in triplicate, and urinary
NGF levels without a consistent value in three
measures are repeated and the values averaged.
When the urinary NGF concentration is higher
than the upper detection limit (250 pg/mL), the
urine samples are diluted to fit the detection
limit. For urine samples with NGF concentrations
lower than the detectable limit but above zero, 
a concentration method is performed using a
column-protein concentration kit (Amicon Ultra-
15; Millipore, Billerica, MA, USA) to measure the
NGF value. Total urinary NGF levels are further nor-
malized by the concentration of urinary creatinine
(NGF/Cr level).
IC/PBS and Urinary NGF
NGF has attracted considerable attention as a
key player in the link between inflammation and
altered pain signaling.6 Intravesical instillation
of NGF in Wistar rats has been shown to induce
bladder hyperactivity.32 In an experimental cysti-
tis rat model, systemic treatment with the NGF-
sequestering molecule partially and significantly
reverses established inflammatory changes.33
Endogenous NGF produced in inflamed tissue is
a crucial mediator of the sensory disorders that are
associated with inflammation and some persistent
pain states.34 Sensitization of sensory pathways by
bladder inflammation or NGF contributes to the
development of hypersensitivity in referral sites,
which suggests that NGF can undergo retrograde
transport to major pelvic ganglia or DRGs.24,35,36
In patients with IC/PBS, neurotrophins [includ-
ing NGF, neurotrophin-3 and glial-cell-derived
neurotrophic factor (GDNF)] have been detected
in the urine.23 Increased expression of NGF is
also present in bladder biopsies from women
with IC/PBS.18,37 Patients with IC/PBS who re-
spond to intravesical BoNT-A injection have been
found to have reduced bladder tissue NGF 
expression.37
In a recent study of urinary NGF expression in
women with IC/PBS, the urinary NGF/Cr levels
were very low when the bladder was not distended
and significantly elevated when the bladder was
full.38 However, urinary NGF/Cr levels were not
correlated with visual analog score (VAS), cysto-
metric bladder capacity at diagnosis, or maximal
bladder capacity during hydrodistention. Patients
who responded to treatment and had an improved
VAS pain score of ≥2 had significantly decreased
NGF/Cr levels compared with non-responders
who had a VAS improvement of < 2. A decrease in
urinary NGF/Cr level was associated with greater
pain reduction and successful response, which
suggests that urinary NGF level can be used as 
a biomarker for detection of the severity of the
bladder condition in IC/PBS.
During bladder inflammation, endogenous
NGF is rapidly upregulated and released to me-
diate sensory and reflex changes.28 A rise in blad-
der NGF in the muscle or urothelium initiates
signals that are transported along the afferent
nerves of the bladder to the DRGs or spinal
cord.28,36 These findings suggest that neural up-
regulation through activation of afferent nerves
occurs peripherally and centrally in subjects with
chronic cystitis. The increase in urinary NGF lev-
els in patients with IC/PBS indicates a higher de-
gree of bladder inflammation. Although treatment
improves bladder pain in some patients, their
urinary NGF levels do not return to those of nor-
mal controls.38 This finding suggests that urinary
NGF level can be monitored as a biomarker for
IC/PBS severity and response to therapy. Long-term
medication and anti-inflammatory management
might be necessary in patients with symptomatic
improvement but chronically elevated urinary
NGF level.
OAB and Urinary NGF
Bladder and urine NGF levels have been found
to be elevated in patients with idiopathic sensory
H.T. Liu, et al
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urgency and IC/PBS.18,23 A recent study has mea-
sured urinary NGF levels in patients with in-
creased bladder sensation, OAB-dry and OAB-wet,
and in a group of control subjects without lower
urinary tract symptoms (LUTS).39 Urinary NGF/
Cr levels were very low in normal controls (mean±
standard deviation, 0.041 ± 0.026) and patients
with increased bladder sensation (0.033 ± 0.02).
Patients with OAB-dry (0.39 ± 0.08) and OAB-wet
(1.70±0.26) had significantly higher urinary NGF/
Cr levels compared with the controls and pa-
tients with increased bladder sensation (Figure 2).
Patients with OAB-wet had significantly higher
urinary NGF levels than those with OAB-dry.
These results suggest that elevated urinary
NGF level plays an important role in mediating
the sensation of urgency in OAB. Increased blad-
der sensation might be caused by increased alert-
ness of bladder fullness or polyuria. Clinically, it
is sometimes difficult to identify these patients
from those with OAB-dry. The results of this
study provide strong evidence for this hypothesis
and suggest that urinary NGF levels can be used
as a biomarker for differential diagnosis of OAB.
The possible reason for the difference in NGF
levels between OAB-dry and OAB-wet might be
the higher percentage of DO in patients with OAB-
wet. Digesu et al investigated a group of 843
women classified with OAB, and 457 (54.2%)
were found to have urodynamically proven DO.40
Hyman et al also found a higher incidence of DO
associated with urge incontinence (OAB-wet) com-
pared with symptoms of urgency and frequency,
nocturia, or difficult urination (75% vs. 36%) in
men with LUTS.41 Taken together, these clinical
observations suggest that urinary NGF level is
strongly associated with the urgency symptom,
and a higher urinary NGF level might have an
impact on the occurrence of DO.
Cerebrovascular Accident and 
Urinary NGF
NGF is essential in nerve growth and regenera-
tion. The level of urinary NGF increases in pa-
tients with IDO and incontinence. Cortical and
brainstem areas are involved in the control of
micturition.42 Cerebrovascular accident (CVA) re-
sults in transient detrusor underactivity in the
acute stage, reduced bladder capacity and unin-
hibited detrusor contractions in the following pe-
riod, and stabilization in the resolution stage.43
In a recent study of urinary NGF levels in 
patients with CVA, the urinary NGF/Cr levels
were found to be significantly higher in CVA pa-
tients than in normal subjects.44 Urinary NGF/Cr
levels correlated well with the severity of neuro-
logical impairment. Patients with no or minimal
neurological impairment had low urinary NGF/Cr
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Figure 2. Patients with overactive bladder-dry and overactive bladder-wet had significantly higher urinary nerve growth fac-
tor and nerve growth factor/creatinine levels compared with the controls and patients with increased bladder sensation.39
NGF = nerve growth factor; Cr = creatinine; HSB = hypersensitive bladder; OAB = overactive bladder.
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levels similar to those of the controls. Patients with
mild/moderate or severe impairment had signifi-
cantly greater urinary NGF levels than those with
no or minimal impairment. However, urinary
NGF/Cr levels were not correlated with age, loca-
tion of CVA, multiplicity of CVA, duration of CVA,
urodynamic findings, or the presence of urge in-
continence, which suggests that urinary NGF is a
result of neurological lesions rather than a cause
of bladder dysfunction in CVA.
NGF is involved in the development and
maintenance of specific peripheral and central
populations of neuronal cells. NGF might oper-
ate through multiple pathways ultimately to reg-
ulate physiological homeostasis and behavioral
coping.45 A previous study has shown that brain-
derived neurotrophic factor mRNA is increased
after stroke.46 In stroke patients, serum neuro-
trophins are significantly associated with clinical
and neuroradiological parameters of brain injury
in the acute phase of stroke, which suggests that
stroke modulates peripheral neurotrophin lev-
els.47 The plasticity of bladder afferents after CVA
might be due to increased circulating NGF lev-
els.48 Increased serum NGF levels might reduce
the excitatory threshold of bladder to DRGs, which
results in increased mechanosensitivity of the blad-
der wall.15 Increased urinary truncated nerve
growth factor receptor (NGF-Rt) levels have also
been found in patients with mild Alzheimer’s dis-
ease.49 It seems rational to hypothesize that
stroke patients with moderate to severe neuro-
logical impairment have increased circulating
NGF, which causes an increase in urinary NGF
level. Systemic neurological impairment might
play a role in elevating NGF and causing OAB
symptoms. Stress-related events might also result
in increased plasma NGF levels and involvement
of neuroendocrine functions.50
BOO and Urinary NGF
The increased level of NGF could trigger 
changes in bladder afferent fibers, which leads 
to reduced threshold or increased excitability.28
NGF expression has been shown to increase in
an in vitro spontaneously hypertensive rat model
with hyperactive voiding and mechanical stress
that mimics BOO.10 Through mechanical stretch-
ing, NGF expression in the bladder wall might
increase, which results in a reduced sensory
threshold for the bladder sensation of urgency 
or a reduced threshold for mediation of detrusor
hyperactivity.51 Incomplete reversibility of neural
plasticity might be responsible for continuing
urge symptoms after surgical intervention for
BOO.52
OAB is frequently associated with BOO in
men with BPH and can resolve after relief of
BOO, but about 50% of patients have persistent
OAB symptoms after surgical intervention for
BPH, which suggests that OAB occurs directly or
independent of BOO.53 In a recent study of uri-
nary NGF/Cr levels in men with BOO, urinary
NGF/Cr levels were low in those with BOO/non-
OAB and significantly elevated in patients with
BOO/OAB and BOO/DO. Urinary NGF/Cr levels
were not significantly different between the
BOO/OAB and BOO/DO groups. The urinary
NGF/Cr levels returned to normal levels after
successful relief of OAB symptoms by medical
treatment.54
Chronic BOO, such as in BPH, can result in
stretching of the urothelium and smooth muscle,
stimulation of NGF production, and alteration of
the afferent nerve pathway. Furthermore, chronic
sensitization of afferent nerves could alter the
conductance of DRGs, which causes increased
excitability and enhanced spinal reflexes. Immu-
nity to NGF prevents afferent nerve plasticity and
occurrence of OAB associated with BOO.55 The
results of this study suggest that elevated NGF
level plays an important role in mediating the
sensation of urgency and causing increased nerve
fiber excitability in BOO. The lower urinary NGF
levels in patients with relief of OAB after treat-
ment further suggests that the pathophysiology
of OAB and DO in patients with BOO involves
NGF over-production in the bladder, which can
return towards normal levels after adequate relief
of BOO.
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IDO and Urinary NGF
DO is a urodynamic diagnosis. OAB is a syndrome
that is characterized by urgency and frequency
with or without urge incontinence.1 Sensory ur-
gency and DO might be involved in the patho-
physiology of this syndrome. Patients with OAB
might not have urodynamic DO, whereas those
with urodynamically proven DO might not pres-
ent with OAB.4 Clinically, it is essential to differ-
entiate DO from patients presenting with OAB
symptoms.
The urothelial release of neurotransmitters
such as acetylcholine and ATP and the expression
of transient receptor potential vanilloid receptor
subfamily 1 (TRPV1) and purinergic receptor
P2X3 strongly imply a role for the urothelium in
human bladder mechanosensation.56–58 The
suburothelial innervation expresses TRPV1, P2X3
receptor, and the sensory neuropeptides substance
P and calcitonin gene-related peptide in the patho-
physiology of human DO.59–61 Intradetrusor in-
jection of BoNT-A decreases immunoreactivity 
of P2X3 and TRPV1 expression in suburothelial
fibers, which correlates with improvement in OAB
symptoms.62
In rats, increased NGF expression with or
without associated inflammation leads to blad-
der overactivity.12,28,32 The bladder mRNA ex-
pression of NGF and TRPV1 is higher in the
unstable bladder following urethral obstruction
in rats.63 Inflammation increases NGF and glial-
cell-derived neurotrophic factor which facilitates
TRPV1 expression and induces thermal hyperal-
gesia.64 These findings suggest that NGF is in-
volved in sensory pathway neuromodulation in
DO. Urinary NGF is highly expressed in patients
with OAB-wet; therefore, we hypothesize that de-
termination of urinary NGF level could serve as a
valuable biomarker for the diagnosis of DO and
monitoring of disease progression of lower urinary
tract dysfunction.39 Moreover, if urinary NGF levels
can be reduced after successful therapy, such as
BoNT-A treatment for DO, measurement of uri-
nary NGF could be a useful objective tool for as-
sessing the therapeutic outcome of DO.
A cross-sectional study has been performed in
143 patients with IDO who had no treatment, or
successful or failed treatment with antimus-
carinic agents. The mean urinary NGF/Cr levels
were significantly higher in 66 patients with un-
treated IDO compared with the controls. Patients
with successfully treated IDO had reduced NGF/
Cr levels, whereas those with failed treatment
did not. Detrusor injection of 100 U BoNT-A was
given to 24 patients who had failed antimus-
carinic treatment. Patients who responded to
BoNT-A treatment had significantly reduced uri-
nary NGF/Cr levels compared with baseline levels;
however, the NGF levels remained significantly
higher at 3 months in patients who failed BoNT-A
treatment.65
Detrusor injection of BoNT-A has been
demonstrated to provide therapeutic improve-
ment for patients with OAB, intractable IDO,
and NDO.66–70 One recent study has found that
BoNT-A injections into the detrusor decrease
NGF bladder tissue levels in patients with
NDO.21 The mechanism responsible for the ef-
fectiveness of BoNT-A on refractory DO is be-
lieved to occur by inhibition of acetylcholine
release from the presynaptic nerve terminals of
the neuromuscular junction.71,72 Detrusor injec-
tion of BoNT-A reduces urgency and decreases
P2X3 and TRPV1 receptor expression in the sub-
urothelium.62 NGF could play an important role
in the connection between suburothelial sensory
fibers and detrusor muscle excitability.73
Antimuscarinic Therapeutic Effect on
Urinary NGF
NGF levels in urine increase in patients with
OAB.29,30,39 Improvement of OAB symptoms
after antimuscarinic therapy reduces urinary
NGF levels.39 Effective antimuscarinic treatment
of OAB might act mainly on the muscarinic re-
ceptors in sensory pathways and alter urinary
NGF production, which in turn reduces the ur-
gency sensation during bladder filling. The re-
duction of urinary NGF levels in OAB patients
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with symptomatic improvement after antimus-
carinic treatment supports the existence of a link
between NGF production and muscarinic recep-
tor activation in OAB.74 Urinary NGF level could
therefore be used as an objective tool to assess
the therapeutic outcome of antimuscarinic treat-
ment for OAB.
In a recent study of urinary NGF levels and
urgency severity score (USS) in patients with OAB
after antimuscarinic therapy and after discontinu-
ing treatment, urinary NGF/Cr levels were signif-
icantly reduced at 3 months in 50 responders who
had a reduction of USS by ≥ 2 but not in 20 non-
responders. After discontinuation of antimus-
carinic treatment for 1 month, however, urinary
NGF/Cr level was elevated in 23 responders and
in five non-responders. The USS significantly
changed with the change of urinary NGF/Cr levels
in responders at different time points. The change
of urinary NGF levels is correlated with the change
of USS after antimuscarinic treatment and dis-
continuation75 (Figure 3).
It is possible that NGF is taken up by sensory
nerves and transported through the central ner-
vous system in a retrograde fashion. Therefore,
NGF production could be a biomarker for neuro-
plasticity via some common pathway involved in
the pathogenesis of OAB.73 A lag response time
between changes in USS and NGF has been noted
in responders. The mechanism for this difference
could be due to a time lag of decreased NGF 
production after antimuscarinic treatment. How-
ever, after antimuscarinic treatment for 3 months,
the USS did not decrease to zero and urinary NGF
levels remained significantly higher than those of
the controls. Another recent study of the changes
in urinary NGF in OAB patients after antimus-
carinic therapy for 12 months has revealed that
the decrease in urinary NGF levels did not reach
a nadir.76 Although OAB symptoms were relieved
after long-term antimuscarinic treatment, urinary
NGF/Cr levels decreased significantly from base-
line to 6 months but remained stationary at 9 and
12 months. The urinary NGF levels at 12 months
after antimuscarinic treatment were significantly
lower than the baseline but were higher than the
controls (Figure 3).
Inflammatory processes are likely to be in-
volved in the etiology of OAB. Tyagi and Chan-
cellor have proposed the hypothesis that local
inflammation is a cause and plays a central role
in the etiology of OAB. Multiplex analysis has re-
vealed increased urinary cytokine levels in a rat
model of cyclophosphamide-induced cystitis.77
Pre-clinical studies have shown that increased
urine levels of monocyte chemoattractant pro-
tein 1 and CXC chemokines CXCL1 are evidence
of bladder inflammation.78 The higher urine 
cytokine levels in OAB-wet relative to OAB-dry
suggest a relationship between OAB symptom
severity and bladder inflammation. Thus, the el-
evated urinary NGF levels after long-term antimus-
carinic treatment might imply the existence of
residual inflammation in the bladder or central
nervous system. Continuation of antimuscarinic
therapy might be necessary to achieve therapeutic
effectiveness.
NDO and Urinary NGF
Increased expression of NGF and brain-derived
neurotrophic factor has been noted in a rat SCI
model.9,79 Increased NGF levels in the bladder,
DRGs, and spinal cord contribute to the emer-
gence of detrusor sphincter dyssynergia (DSD) that
is partially mediated by C-fiber bladder afferents
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Figure 3. Changes in urinary nerve growth factor levels with
time in patients with overactive bladder-wet who have been
successfully treated with antimuscarinic agents.76 NGF =
nerve growth factor; Cr = creatinine.
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after SCI.80 The SCI rats with higher severity of
autonomic dysreflexia (AD) are correlated with
higher NGF expression in lumbosacral seg-
ments.79 Immunoneutralization of NGF in the
spinal cord suppresses NGF levels in the lum-
bosacral DRGs and DSD.82 In human bladders,
increased NGF expression has been found in pa-
tients with SCI and NDO.29 Detrusor injection of
BoNT-A can reduce DO as well as the expression
of NGF.21 It is possible to monitor the changes in
urinary NGF levels as biomarkers for the degree
of DSD and AD in patients with SCI and NDO.
Urinary NGF levels have been measured in
patients with NDO due to SCI at baseline, after
antimuscarinic treatment, and after BoNT-A in-
jections.65 The urinary NGF/Cr levels were signif-
icantly elevated compared with those in the
controls. Patients with DSD and AD had a higher
NGF/Cr level compared with those without AD.
After BoNT-A injections, a successful result was
achieved in 14 (74%) patients with NDO. Analysis
of the therapeutic outcome has revealed a signifi-
cant decrease in urinary NGF/Cr level in BoNT-A
responders with NDO but no significant decrease
in non-responders of NDO at 3 months. Persistent
low urinary NGF/Cr levels compared with base-
line were also detected at 6–12 months in patients
with NDO who had a long-lasting BoNT-A effect
for > 6 months.
Mixed Urinary Incontinence and 
Urinary NGF
The presence of OAB, urodynamic DO, and urge
incontinence can complicate the diagnosis and
management of stress urinary incontinence (SUI)
in women. Compared with women with SUI,
women with urge incontinence and mixed urinary
incontinence have reported not only significantly
greater urinary urgency intensity and more epi-
sodes of incontinence but also significantly worse
health-related quality of life.83 There is a close as-
sociation between SUI, OAB, and DO. OAB symp-
toms might only resolve in about 50% of patients
with mixed urodynamic stress incontinence (USI)
and DO after anti-incontinence surgery such as
the tension-free vaginal tape procedure.84–86 How-
ever, persistent SUI, persistent OAB symptoms,
or de novo DO might occur in women who have
undergone an anti-incontinence procedure which
results in BOO.86 A recent study has also revealed
that in patients with urge syndrome after a pubo-
vaginal sling procedure, 85.9% of patients had 
a chronic condition, and 83.3% of those with 
de novo DO had preoperative urge syndrome.87
It would be important if we could detect DO 
before undertaking anti-incontinence surgery in
patients with mixed urinary incontinence.
Among a cohort of women with urinary in-
continence, urinary NGF/Cr levels were low in
the controls and in women with pure USI. The
NGF/Cr levels were significantly higher in
women with mixed USI and DO than in controls
and in those with pure USI but were similar to
the levels in women with pure DO. The NGF/Cr
levels were undetectable in women with persis-
tent USI but were significantly higher in those
with de novo DO after anti-incontinence surgery,
compared with the controls and USI patients.88
Effect of Bladder Volume on Urinary NGF
Patients with OAB usually have a smaller bladder
capacity and hypersensitivity, whereas non-OAB
patients can tolerate a large bladder capacity when
they have the urge to void.89 Stretch of bladder
smooth muscle cells stimulates increased NGF
production which is associated with hyperactive
voiding in spontaneously hypertensive rats.10 The
difference of bladder sensitivity to volume increase
might be due to abnormal secretion of sensory
proteins such as NGF or overexpression of sensory
receptors in the bladder wall with a small blad-
der volume or during bladder distention.
Urinary NGF levels have been measured in 39
patients with OAB and in 35 control subjects
without LUTSs. Urine samples were collected at
the first sensation of bladder filling (FSF) and at
urge sensation (US), respectively, in both groups.
Urinary NGF/Cr levels were very low at FSF and
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were significantly increased at US in normal con-
trols. Patients with OAB had significantly higher
urinary NGF/Cr levels at FSF and US compared
with those in the controls. The urinary NGF/Cr lev-
els showed a non-significant change between FSF
and US in OAB patients, but the NGF/Cr levels of
OAB patients at FSF were significantly higher than
those in the controls at US.90 The results of this
study suggest that urinary NGF increases physio-
logically in normal subjects at the urge to void but
increases pathologically in OAB patients with a
small bladder volume and at urgency sensation.
Bladder distention can stretch the urothelium,
and evidence has shown that ATP released from
the urothelium during bladder distention can pro-
voke a sensation of bladder filling.91 Physiologi-
cally, the release of urinary NGF increases with
increased bladder volume, but NGF production
might be limited until a threshold level. When
the bladder is fully distended, a cascade of neu-
romediators might be released from the urothe-
lium, which act on receptors in the suburothelial
afferents, which might induce the sensation of
urge to void.92 However, in patients with bladder
dysfunction such as hypersensitivity, IC/PBS, or
OAB, sensitization of bladder afferents or lower-
ing the threshold of sensory firing by NGF might
occur, which induces urgency or urge incontinence
during bladder filling at a sub-threshold volume.93
Urinary NGF Levels in Natural or
Catheter Bladder Filling
Previous investigations have shown that urinary
NGF levels are elevated in patients with OAB-dry,
and are even higher in patients with OAB-wet
compared with normal controls and patients
with increased bladder sensation.29,39 Whether
the urinary NGF is produced by bladder wall dis-
tention or from other sites of the urinary tract has
not yet been elucidated. Urinary urgency occurs
when the bladder is full, and rapid distention
during urodynamic studies can induce urgency
sensation or DO. Could these different conditions
have similar levels of NGF production?
In a recent study, urinary NGF/Cr levels in 
natural-filling (drinking water) were significantly
greater than those with catheter-filling (infused
by normal saline) in OAB-wet or urodynamic
DO subgroups.94 Urinary NGF/Cr levels were also
significantly elevated in patients with OAB-wet
or urodynamic DO (Table 1). This study provides
results of urinary NGF in patients with OAB-wet
or DO that were similar to those in previous stud-
ies. One particularly interesting finding was that
urinary NGF levels in OAB-wet increased only in
natural-filling but not in catheter-filling. The NGF
levels in OAB-dry were also slightly increased in
natural-filling compared with catheter-filling; how-
ever, no difference was noted between natural
and catheter-filling in the controls. This suggests
that urinary NGF could be produced secondary
to bladder dysfunction, whereas the severity of
bladder dysfunction results in different OAB con-
ditions. A longer duration of bladder distention
might affect the production of urinary NGF in
natural-filling.
Comparison of Urinary NGF Between
OAB and IC/PBS
The clinical symptoms of IC/PBS and OAB are
similar except that bladder pain typically pres-
ents in IC/PBS, and urgency or urge incontinence
presents in OAB-dry and OAB-wet. Although uri-
nary NGF as a biomarker can be a sensitive mo-
lecular diagnostic tool for OAB,29,39 recent research
has revealed that urinary NGF levels are also in-
creased in patients with IC/PBS.65 Thus, a more
detailed analysis of urinary biomarkers is needed
to establish their role as a non-invasive diagnos-
tic tool for the differential diagnosis of IC/PBS
and OAB.
In a recent study that has compared urinary
NGF levels among IC/PBS, OAB-dry, and OAB-wet,
increased urinary NGF levels have been found in
women with IC/PBS and OAB-wet or DO but not
in controls and women with OAB-dry or hyper-
sensitive bladder.95 Urinary NGF/Cr levels did
not differ significantly between patients with
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IC/PBS and OAB-wet or DO. However, urinary
NGF levels were significantly higher in women
with IC/PBS than in those with OAB-dry or hy-
persensitive bladder (Figure 4). Using receiver
operating characteristic curves to assess urinary
NGF/Cr levels in patients with IC/PBS and OAB-
dry, the diagnosis of IC/PBS could be achieved
with a sensitivity and specificity of 75% and
56.6%, respectively, based on a urinary NGF/Cr
cut-off value of 0.015.
The symptoms of IC/PBS and OAB-wet are dis-
tinct, and patients with IC/PBS have bladder pain
and those with OAB-wet have urge incontinence.
Thus, there is no need for a biomarker to make
the differential diagnosis between IC/PBS and
OAB-wet. There is potential for the use of a bio-
marker for non-invasive differential diagnosis
between IC/PBS and OAB-dry or hypersensitive
bladder. Diagnosis of IC/PBS by cystoscopic hy-
drodistention under general anesthesia could
thus be avoided in most patients.
Previous histological studies on tissue biopsies
from patients with IC/PBS have documented infil-
tration of mast cells, macrophages, and eosinophils
as a consistent finding, and the significant associa-
tion for T- and B-cell staining was similar to that
for overall inflammation.96 Therefore, an in-
creased NGF level in the bladder or urine indi-
cates the presence of chronic inflammation in
Table 1. Total urinary nerve growth factor and nerve growth factor/creatinine levels in symptomatic and
urodynamic subgroups at natural filling and catheter filling
Subgroups
Natural-filling Natural-filling Catheter-filling Catheter-filling 
Total NGF NGF/Cr Total NGF NGF/Cr
Symptomatic
Control (n = 28) 1.52 ± 4.05 0.085 ± 0.219 1.06 ± 3.37 0.395 ± 0.955
OAB-dry (n = 28) 6.92 ± 15.4 0.296 ± 0.556 1.81 ± 6.32 0.243 ± 1.20
OAB-wet (n = 25) 49.3 ± 97.9 1.66 ± 3.30 3.17 ± 13.3 0.388 ± 1.84
ANOVA Control vs. OAB-wet, Control vs. OAB-wet, All NS All NS
p = 0.013 p = 0.015
OAB-dry vs. OAB-wet, OAB-dry vs. OAB-wet, 
p = 0.031 p = 0.040
Urodynamic
Normal (n = 27) 1.76 ± 4.18 0.090 ± 0.217 1.02 ± 3.43 0.242 ± 0.775
HSB (n = 30) 6.21 ± 14.4 0.252 ± 0.522 1.69 ± 6.11 0.309 ± 1.15
DO (n = 22) 55.8 ± 103.0 1.88 ± 3.47 3.60 ± 14.1 0.441 ± 1.96
ANOVA Normal vs. DO, Normal vs. DO, All NS All NS
p = 0.009 p = 0.010
HSB vs. DO, HSB vs. DO,
p = 0.013 p = 0.016
NGF = nerve growth factor; Cr = creatinine; OAB = overactive bladder; ANOVA = analysis of variance; NS = not significant; HSB =
hypersensitive bladder; DO = detrusor overactivity.
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Figure 4. Urinary nerve growth factor/creatinine levels were
not significantly different between patients with interstitial
cystitis/painful bladder syndrome and overactive bladder-wet
or detrusor overactivity. However, urinary nerve growth fac-
tor levels were significantly higher in women with interstitial
cystitis/painful bladder syndrome than in those with overac-
tive bladder-dry.95 NGF=nerve growth factor; Cr=creatinine;
OAB = overactive bladder; IC = interstitial cystitis.
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patients with IC/PBS. Recent biopsy studies on
OAB patients have reported signs of mild to
moderate inflammation in the bladder wall.97
Although urinary NGF levels in IC/PBS and OAB-
wet are similar, the underlying inflammatory pro-
tein expression responsible for bladder pain in
IC/PBS and urge incontinence in OAB-wet needs
clarification. The urinary proteome is a potential,
easily accessible source of biomarkers for inflam-
matory bladder disorders, including IC/PBS and
OAB. Analysis of multiple urinary proteins is a
convenient approach to monitor the activation
of inflammatory cells in bladder tissue,98 and a
detailed diagnosis by proteomic study using a
urine sample might be feasible to differentiate
these two bladder disorders.
Urinary NGF in Urinary Tract Diseases
Several urological diseases, including bacterial cys-
titis, lower ureteral stone, and urothelial cell carci-
noma, might develop storage symptoms that
mimic OAB or IC/PBS. It is essential to understand
whether these disorders can also produce high lev-
els of urinary NGF and whether the increased NGF
production is related to the associated storage
symptoms in these diseases76 (Table 2).
Bacterial cystitis
Patients with acute bacterial cystitis with or with-
out OAB symptoms have elevated urinary NGF/Cr
levels compared with controls. The urinary NGF/
Cr levels in patients with urinary tract infection
Table 2. Urinary nerve growth factor levels in patients with different lower urinary tract diseases
n NGF (pg/mL) NGF/Cr Statistics*†
Control 49 2.27 ± 0.87 0.05 ± 0.02
OAB-dry 26 7.19 ± 3.06 0.31 ± 0.11 p = 0.000*, p = 0.033†
OAB-wet 22 54.3 ± 22.1 1.83 ± 0.74 p = 0.012*
IC/PBS 60 69.7 ± 14.0 1.73 ± 0.44 p = 0.000*, p = 0.902†
OAB 
Natural filling 14 40.1 ± 16.1 0.96 ± 0.29 Natural vs. KCl, p = 0.102
N/S filling 14 0.00 0.00 Natural vs. N/S, p = 0.005
KCl test 14 3.18 ± 1.71 0.46 ± 0.21 KCl vs. N/S, p = 0.045
IC/PBS
Natural filling 9 75.47 ± 44.64 1.13 ± 0.50 Natural vs. KCl, p = 0.115
N/S filling 9 1.25 ± 1.25 0.15 ± 0.15 Natural vs. N/S, p = 0.052
KCl test 9 1.07 ± 0.74 0.17 ± 0.14 KCl vs. N/S, p = 0.914
UTI
Before treatment 40 99.0 ± 19.2 2.97 ± 0.86 p = 0.000*, p = 0.378†
After treatment 30 33.5 ± 18.3 1.09 ± 0.67 p = 0.000*, p = 0.467†
Renal stone
No UTI 18 30.5 ± 9.36 0.48 ± 0.15 p = 0.000*, p = 0.130†
With UTI 7 232.9 ± 64.9 4.68 ± 1.72 p = 0.000*, p = 0.000†
Ureteral stone
With OAB 32 61.2 ± 20.7 0.81 ± 0.19 p = 0.000*, p = 0.248†
Without OAB 19 40.3 ± 14.9 0.56 ± 0.17 p = 0.000*, p = 0.066†
Bladder tumor
TCC 23 73.7 ± 41.5 1.52 ± 0.79 p = 0.000 *, p = 0.737†
Benign tumor 2 0 0
Results are presented as mean ± standard error. *Comparison of NGF/Cr with the controls, †comparison of NGF/Cr with OAB-wet.
NGF = nerve growth factor; Cr = creatinine; OAB = overactive bladder; IC/PBS = interstitial cystitis/painful bladder syndrome;
N/S = normal saline; UTI = urinary tract infection; TCC = transitional cell carcinoma.
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(UTI) is no different from that in OAB-wet or
IC/PBS but is significantly greater than in OAB-
dry. The urinary NGF/Cr levels in patients who
have UTI-associated OAB and those without
OAB at baseline do not differ significantly. The
urinary NGF/Cr level decreases significantly after
antibiotic treatment for 1 week but remains signif-
icantly higher than in the controls. The urinary
NGF/Cr decreases significantly in patients without
OAB after treatment but remains high in patients
who have persistent OAB after treatment. Among
patients who have baseline and post-treatment
data, urinary NGF/Cr levels decrease significantly
in those without OAB and remain high in those
with OAB after UTI treatment (Figure 5).
Ureteral stone and renal stone
Urinary NGF/Cr levels in patients who have urinary
tract stones without UTI are significantly higher
than in controls or those with OAB-dry but are
significantly lower than in patients with IC/PBS
and OAB-wet. There is no significant difference
in urinary NGF/Cr levels between patients with
renal or ureteral stones. Urinary NGF/Cr levels
do not differ significantly in patients with renal
stones without UTI compared with those with
OAB-wet or IC/PBS but they are significantly
lower in patients with ureteral stones compared
with those with OAB-wet or IC/PBS. Patients
with renal stones and UTI show a 10-fold signifi-
cantly higher urinary NGF/Cr level than those
without UTI. The urinary NGF/Cr level is not 
significantly different between patients who have
ureteral stones associated with OAB and those
without OAB.
Bladder urothelial carcinoma and 
benign tumor
Patients with urothelial cancer also have elevated
urinary NGF/Cr levels compared with controls.
However, the NGF level in patients with benign
bladder tumor is not detectable. The urinary NGF
levels in patients with urothelial transitional cell
carcinoma (TCC) are not significantly different
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Figure 5. Urinary nerve growth factor/creatinine levels in patients with bacterial cystitis at baseline and after treatment.76
SEM = standard error of the mean; NGF = nerve growth factor; Cr = creatinine; OAB = overactive bladder; IC = interstitial
cystitis; UTI = urinary tract infection; Tx = treatment. *p < 0.05.
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from those in patients with IC/PBS or OAB-wet
but are significantly higher than in patients with
OAB-dry. The urinary NGF/Cr level is significantly
higher in high-grade than low-grade TCC. Patients
with ureteral TCC and muscle-invasive TCC do not
have a significantly higher urinary NGF/Cr level.
Other Considerations of Using Urinary
NGF as a Biomarker for OAB
NGF is not the sole protein that is responsible for
OAB; therefore, measurement of other inflamma-
tory proteins in the urine, or comparison of uri-
nary NGF levels at different bladder volumes and
different severity of urgencies could clarify this
question. In addition, collection of urine sam-
ples at different time points might have the effect
of increased urothelial uptake, whereas delayed
preparation of urine samples might result in pro-
teolytic degradation of urinary NGF, and these
factors might influence the levels of urinary NGF.
Thus, standardization of urine sample collection
and enrollment of larger groups of patients in
further studies are necessary before we conclude
that urinary NGF levels can be a biomarker of
OAB.
Conclusions
Measurement of urinary NGF levels in patients
with OAB and LUTSs provides insight into the
underlying pathophysiology of these conditions.
Urinary NGF levels could augment the use of
urodynamic studies for differential diagnosis of
OAB and urinary incontinence. The results of re-
cent studies suggest that urinary NGF level is a
promising biomarker for the differential diagno-
sis of OAB and could serve as a useful objective
test to evaluate IDO and NDO treatment out-
come. However, because urinary NGF level can
also increase in many lower urinary tract dis-
eases, such as stones, tumors, acute bacterial in-
fection, and IC/PBS, it is important to exclude
these diseases before a diagnosis of OAB is made.
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